New therapies for pancreatic cancer: Current standard

Journal of the Pancreas

Volumn 8, Issue 1 SUPPL, 2007, Pages 98-101

  Reni, Michele ^a   Cereda, Stefano ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Capecitabine; Drug therapy; Erlotinib; Fluorouracil; Gemcitabine; Pancreatic neoplasms; Radiotherapy; Review; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; HUMAN; MULTIMODALITY CANCER THERAPY; PANCREAS RESECTION; PANCREAS TUMOR; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RADIOTHERAPY;

EID: 66249113959     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Neuhaus P, Oettle H, Post S, Gellert K, Schramm H, Zulke C, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. J Clin Oncol 2005; 23(16S):4013.
2. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-10. [PMID 15028824]
3. Regine WF, Winter KW, Abrams R, Safran H, Hoffman JP, Konski A, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 2006; 24(18S):4007.
4. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002; 20:3130-6. [PMID 12118027]
5. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899-903. [PMID 4015380]
6. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230:776-82. [PMID 10615932]
7. Huguet F, André T, Hammel P, Artru P, Balosso J, Ruszniewski P, et al. Chemoradiotherapy (CRT) after chemotherapy (CT) improves survival for locallyadvanced (LA) pancreatic cancer patients: Retrospective analysis of 181 patients enrolled in prospective phases II and III GERCOR studies. J Clin Oncol 2006; 23(16S):4095.
8. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995; 31:882-7. [PMID 7646915]
9. Taylor I. Should further studies of chemotherapy be carried out in pancreatic cancer? Eur J Cancer 1993; 29:1076-78. [PMID 7686019]
10. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600. [PMID 8879373]
11. Palmer K, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81:882-5. [PMID 8044610]
12. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvement in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
13. Poplin E, Levy DE, Berlin J, Rothenberg ML, O'Dwyer PJ, Cella D, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006; 24(18S):4004.
14. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270-75. [PMID 12149301]
15. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3296-302. [PMID 12947065]
16. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22:3776-83. [PMID 15365074]
17. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebocontrolled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87:161-7. [PMID 12107836]
18. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA; Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19:3477-55. [PMID 11481349]
19. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16:1639-45. [PMID 16087696]
20. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430-38. [PMID 15084616]
21. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16. [PMID 15908661]
22. Banu E, Oudard S, Banu A, Fodor A, Landi B, Lecomte T, et al. Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC). J Clin Oncol (Meeting Abstracts) 2005 23: 4101.
23. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Gastrointestinal Cancers Symposium 2005; Abstract 77.
24. Cunningham D, Chau I, Stocken C, Davies C, Dunn J, Valle J, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 2005; 3(4 Suppl):12. (Abstract PS11)
25. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005; 23(16S): LBA4010.
26. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6:369-76. [PMID 15925814]
27. Reni M, Bonetto E, Cordio S, Passoni P, Milandri C, Cereda S, et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology 2006; 6:454-63. [PMID 16847383]
28. Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001; 19:2679-86. [PMID 11352960]
29. Dell'Oro S, Reni M, Bonetto E, Panucci MG, Viganò MG, Zerbi A, et al. Intensified PEFG regimen in stage III-IV pancreatic adenocarcinoma: a phase I trial Ann Oncol 2004; 15(Suppl. 3):iii242. (Abstract 919P).
30. Reni M, Cereda S, Bonetto E, Vigano MG, Passoni P, Zerbi A, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2006 [Epub ahead of print]. [PMID 16807732]